Changes in Serum Osteocalcin are Not Associated with Changes in Glucose or Insulin for Osteoporotic Patients Treated with Bisphosphonate
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Bisphosphonate is used in osteoporosis treatment to repress osteoclast activity, which then decreases levels of osteocalcin (OC). OC, a protein secreted by osteo-blasts and released from the bone matrix during osteoclastic bone resorption, has been found to control blood glucose levels by increasing insulin production and sensitivity. The question addressed in this study is whether decreasing OC through bisphosphonate treatment will provoke a change in glucose homeostasis. Methods: Eighty-four patients with osteoporosis were treated with once-weekly risedronate 35 mg and cholecalciferol 5,600 IU. We measured fasting plasma glucose (FPG), insulin, and undercarboxylated (Glu) and carboxylated (Gla) OC levels at baseline and after 16 weeks. To estimate insulin resistance (IR) and β-cell function (B)%, homeostasis model assessment (HOMA)-IR and HOMA-B% were also calculated, respectively. Results: The mean FPG level in total sub -jects increased significantly from 5.3 to 5.5 mmol/L, but no changes in blood glucose were noted in the 24 subjects with impaired fasting glucose. Glu and Gla OC levels de-clined significantly after treatment. No correlations were observed between changes in OC and changes in glucose, however. Conclusions: Bisphosphonate treatment for os-teoporosis reduced OC, but this change was not associated with changes in glucose me-tabolism.
Abstract
Background: Bisphosphonate is used in osteoporosis treatment to repress osteoclast activity, which then decreases levels of osteocalcin (OC). OC, a protein secreted by osteo-blasts and released from the bone matrix during osteoclastic bone resorption, has been found to control blood glucose levels by increasing insulin production and sensitivity. The question addressed in this study is whether decreasing OC through bisphosphonate treatment will provoke a change in glucose homeostasis. Methods: Eighty-four patients with osteoporosis were treated with once-weekly risedronate 35 mg and cholecalciferol 5,600 IU. We measured fasting plasma glucose (FPG), insulin, and undercarboxylated (Glu) and carboxylated (Gla) OC levels at baseline and after 16 weeks. To estimate insulin resistance (IR) and β-cell function (B)%, homeostasis model assessment (HOMA)-IR and HOMA-B% were also calculated, respectively. Results: The mean FPG level in total sub -jects increased significantly from 5.3 to 5.5 mmol/L, but no changes in blood glucose were noted in the 24 subjects with impaired fasting glucose. Glu and Gla OC levels de-clined significantly after treatment. No correlations were observed between changes in OC and changes in glucose, however. Conclusions: Bisphosphonate treatment for os-teoporosis reduced OC, but this change was not associated with changes in glucose me-tabolism.
참고문헌 (20)
- Motyl KJ, "Bone and glucose meta bolism: a two-way street", Arch Biochem Biophys, 503, pp.2~10 (2010)
- Ferron M, "An ELISA-based method to quantify osteocalcin carboxylation in mice", Biochem Biophys Res Commun, 397, pp.691~696 (2010)
- Lee NK, "Endocrine regulation of energy metabolism by the skeleton", Cell, 130, pp.456~469 (2007)
- Ferron M, "Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice", Proc Natl Acad Sci U S A, 105, pp.5266~5270 (2008)
- Fernández-Real JM, "The relationship of serum osteocalcin concentration to insulin secretion, sensitivity, and disposal with hypocaloric diet and resistance training", J Clin Endocrinol Metab, 94, pp.237~245 (2009)
- Im JA, "Relationship between osteocalcin and glucose metabolism in postmenopausal women", Clin Chim Acta, 396, pp.66~69 (2008)
- Kindblom JM, "Plasma osteocalcin is inversely related to fat mass and plasma glucose in elderly Swedish men", J Bone Miner Res, 24, pp.785~791 (2009)
- Liberman UA, "Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group", N Engl J Med, 333, pp.1437~1443 (1995)
- Chung HY, "Efficacy of risedronate with cholecalciferol on 25-hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis", Clin Endocrinol (Oxf), 74, pp.699~704 (2011)
- Kanazawa I, "Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus", J Clin Endocrinol Metab, 94, pp.45~49 (2009)
- Yeap BB, "Reduced serum total osteocalcin is associated with metabolic syndrome in older men via waist circumference, hyperglycemia, and triglyceride levels", Eur J Endocrinol, 163, pp.265~272 (2010)
- Hwang YC, "The uncarboxylated form of osteocalcin is associated with improved glucose tolerance and enhanced beta-cell function in middle-aged male subjects", Diabetes Metab Res Rev, 25, pp.768~772 (2009)
- Iki M, "Serum undercarboxylated osteocalcin levels are inversely associated with glycemic status and insulin resistance in an elderly Japanese male population: Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) Study", Osteoporos Int, 23, pp.761~770 (2012)
- Shea MK, "Gamma-carboxylation of osteocalcin and insulin resistance in older men and women", Am J Clin Nutr, 90, pp.1230~1235 (2009)
- Schwartz AV, "Effects of antiresorptive therapies on glucose metabolism: Results from the FIT, HORIZON-PFT and FREEDOM trials", J Bone Miner Res (2013)
- Vestergaard P., "Risk of newly diagnosed type 2 diabetes is reduced in users of alendronate", Calcif Tissue Int, 89, pp.265~270 (2011)
- Dane C, "Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis", Gynecol Endocrinol, 23, pp.398~403 (2007)
- Kanaya AM, "Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen", progestin Replacement Study. A randomized, double-blind, placebo-controlled trial, 2003, pp.138, 1~9
- Margolis KL, "Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial", Diabetologia, 47, pp.1175~1187 (2004)
- Hwang YC, "Circulating osteocalcin level is not associated with incident type 2 diabetes in middle-aged male subjects: mean 8.4-year retrospective follow-up study", Diabetes Care, 35, pp.1919~1924 (2012)